Age at symptom onset and long-term survival in patients with neurofibromatosis Type 2

Journal of Neurosurgery

Volumn 99, Issue 3, 2003, Pages 480-483

  Otsuka, Goro ^a   Saito, Kiyoshi ^a   Nagatani, Tetsuya ^a   Yoshida, Jun ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Age; Long term follow up; Neurofibromatosis; Survival; Type 2

Indexed keywords

ADULT; ARTICLE; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; NEURILEMOMA; NEUROFIBROMATOSIS; ONSET AGE; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME;

EID: 0042421988     PISSN: 00223085     EISSN: None     Source Type: Journal    
DOI: 10.3171/jns.2003.99.3.0480     Document Type: Article

References (20)

1. Aguiar PH, Tatagiba M, Samii M, et al: The comparison between the growth fraction of bilateral vestibular schwannomas in neurofibromatosis 2 (NF2) and unilateral vestibular schwannomas using the monoclonal antibody MIB 1. Acta Neurochir 134:40-45, 1995
2. Anonymous: National Institutes of Health Consensus Development Conference Statement on Acoustic Neuroma, December 11-13, 1991. The Consensus Development Panel. Arch Neurol 51:201-207, 1994
3. Antinheimo J, Haapasalo H, Haltia M, et al: Proliferation potential and histological features in neurofibromatosis 2-associated and sporadic meningiomas. J Neurosurg 87:610-614, 1997
4. The Committee of Brain Tumor Registry of Japan: Report of Brain Tumor Registry of Japan (1969-1993), ed 10. Neurol Med Chir 40 (Suppl):1-106, 2000
5. Eldridge R: Central neurofibromatosis with bilateral acoustic neuroma. Adv Neurol 29:57-65, 1981
6. Evans DG, Huson SM, Donnai D, et al: A clinical study of type 2 neurofibromatosis. Q J Med 84:603-618, 1992
7. Evans DGR, Huson SM, Donnai D, et al: A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet 29:841-846, 1992
8. Evans DGR, Huson SM, Donnai D, et al: A genetic study of type 2 neurofibromatosis in the United Kingdom. II. Guidelines for genetic counselling. J Med Genet 29:847-852, 1992
9. Gutmann DH, Aylsworth A, Carey JC, et al: The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 278:51-57, 1997
10. MacCollin M, Braverman N, Viskochil D, et al: A point mutation associated with a severe phenotype of neurofibromatosis 2. Ann Neurol 40:440-445, 1996
11. Martuza RL, Ojemann RG: Bilateral acoustic neuromas: clinical aspects, pathogenesis, and treatment. Neurosurgery 10:1-12, 1982
12. Mulvihill JJ, Parry DM, Sherman JL, et al: NIH conference. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis). An update. Ann Intern Med 113:39-52, 1990
13. Parry DM, Eldridge R, Kaiser-Kupfer MI, et al: Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet 52: 450-461, 1994
14. Parry DM, MacCollin M, Kaiser-Kupfer KM, et al: Germ-line mutations in neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. Am J Hum Genet 59: 529-539, 1996
15. Rouleau GA, Merel P, Lutchman M, et al: Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 363:515-521, 1993
16. Ruttledge MH, Andermann AA, Phelan CM, et al: Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am J Hum Genet 59:331-342, 1996
17. Samii M, Matthies C, Tatagiba M: Management of vestibular schwannomas (acoustic neuromas): auditory and facial nerve function after resection of 120 vestibular schwannomas in patients with neurofibromatosis 2. Neurosurgery 40:696-706, 1997
18. Subach BR, Kondziolka D, Lunsford LD, et al: Stereotactic radiosurgery in the management of acoustic neuromas associated with neurofibromatosis Type 2. J Neurosurg 90:815-822, 1999
19. Trofatter JA, MacCollin MM, Rutter JL, et al: A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 72:791-800, 1993
20. Yoshida J, Shitara N, Takakura K, et al: A statistical study of central neurofibromatosis in Japan, in Ishibashi Y, Hori Y (eds): Tuberous Sclerosis and Neurofibromatosis: Epidemiology, Pathophysiology, Biology and Management. New York: Elsevier Science Publishers, 1990, pp 315-321